Nowadays, Tirzepatide, a molecule with combined agonist action on GLP1 and glucose-dependent insulinotropic peptide, has demonstrated effectiveness in weight loss and improvement in metabolic parameters (especially glucose control), as well as in NAFLD markers. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.